Greenphire opens London office
Greenphire, a provider of payment technologies for the clinical trials industry, has announced an expansion into the European market with the opening of an office in London. The addition is a key part of the 2013 strategic plan and is designed to support the increasing global demand for Greenphire’s products and services. Associate Web Editor Mia Burns interviewed Sam Whitaker, CEO, Greenphire.
Q: Where else in Europe does Greenphire plan to expand?
A: Greenphire already has a broad client base in Europe and has capabilities to serve 180 countries, with many of our customers being global pharmaceutical companies. We plan to use the new office in London as a home base to directly support our clients conducting studies throughout Europe, offering customer service support locally and in local languages, while providing a European hub to build relationships with new clients based in the geography.
Q: Are these expansions physical (as in new buildings in new locations) or does the term expansion refer to the services that Greenphire will offer?
A: Greenphire already offers technology products that support clients worldwide, including clients based in Europe such as Bavarian Nordic. The expansion is physical with the new office now up-and-running in London and we plan to hire additional staff to support our European clients, as well as to further develop our business in Europe.
Q: What are some of the therapeutic areas that the company covers in its services?
A: Greenphire’s payment technology solutions are truly agnostic in terms of therapy area and we have active studies within our portfolio covering the spectrum of clinical therapy areas including diabetes, cardiovascular health, women's health, and oncology.
Q: Can you elaborate on the commercial success that Greenphire has experienced during the last two years?
A: We released our flagship product, eClinicalGPS, in 2011. The system, which automates payment execution globally, has seen wide adoption across the clinical trials industry since that point, including its first enterprise adoption mid-2012 by a top 20 pharmaceutical company, two other enterprise adopters in late 2012/early 2013, and multiple sponsors choosing to work with the technologies on a trial-by-trial basis. Greenphire's ClinCard solution, which enables clinical research subjects to receive reimbursements and stipend payments instantly through a branded debit card system, has also seen increasing adoption at both the site and sponsor level. The number of clients that we serve across all of our solutions has tripled since 2011 and we are also delighted to have doubled our staff twice in the past two years and added significantly to the depth and breadth of the company's management team.
Q: Where would you like to see Greenphire in five years?
A: Over the next five years we expect to continue to grow at the same fast pace that we have enjoyed since the company’s launch, while establishing a significant presence in Europe and Asia, growing revenues and staff, and developing additional strategic partnerships with key industry players. We also anticipate having at least a dozen products, focused primarily on leveraging our payment platform to produce complex data and analytics, ultimately driving strategic value for our clients. What sets Greenphire apart is that we value our unique company culture built on fun, innovation, and trust, and we hope to maintain that culture as we grow and expand internationally.
Posted: September 2013